Abstract 108P
Background
The All Wales Medical Genomics Service (AWMGS) has been a UK leader delivering precision medicine services since 2009, and targeted circulating tumour DNA (ctDNA) testing since 2016. The QuicDNA biomarker study aims to evaluate whether the addition of a liquid biopsy earlier in the lung cancer patient pathway to facilitate detection of genomic changes using ctDNA can accelerate access to targeted therapies in Wales. The study aims to perform ctDNA NGS for 1,260 patients within a 2-year period and perform statistical analysis with a matched comparison group of 1,260 patients.
Methods
We report the in-house validation and implementation of the Illumina TruSight Oncology 500 ctDNA NGS assay and NovaSeq 6000TM for the detection of variants with potential therapeutic implications in patients with suspected NSCLC, thus enabling non-invasive testing of all targets with an associated therapy currently licensed for use in NSCLC in the UK. A virtual lung panel reporting single nucleotide variants and small insertions and deletions (EGFR, KRAS, BRAF, MET), along with gene fusions (involving ALK, ROS1, RET, NTRK1, NTRK2, NTRK3) was developed for the detection of variants in the region of 0.5% variant allele frequency. The test is being introduced across Wales gradually region by region, but will be provided for all Welsh patients with suspected NSCLC by the end of 2024.
Results
During validation the test achieved a sensitivity of >98%. Specificity was challenging to assess due to a lack of suitable control material and was preliminarily estimated to be >74%. Results of the testing performed over the first 6 months will be presented, including interesting cases with actionable variants in EGFR and MET. An interim report on the detection rate for actionable variants, the timing of reporting within the diagnostic pathway, and concordance with tissue testing will also be presented.
Conclusions
Early results indicate that the addition of comprehensive liquid biopsy testing earlier in the patient pathway is able to guide treatment decision-making and is predicted to lead to better patient outcomes.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
All Wales Medical Genomics Service.
Funding
Illumina, Welsh Government (Health & Care Research Wales), AstraZeneca, Bayer, Amgen, Lilly, The Moondance Charitable Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
10P - An adapted CGP-based model to interpret POLE mutations in endometrial cancer
Presenter: Rita Trozzi
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Reconstructing tumour evolution of single cells using both somatic mutations and copy-number alterations
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Swiss-PO: Molecular modelling for precision oncology
Presenter: Fanny Krebs
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - A novel algorithm for predicting variant detectability in oncogenomic analysis
Presenter: Alper Akkuş
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - expHRD: An algorithm for the transcriptome-based estimation of homologous recombination deficiency score
Presenter: Jin-Ku Lee
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - ClinBioNGS: An integrated clinical bioinformatics pipeline for the analysis of somatic NGS cancer panels
Presenter: Xavier Sole
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Investigation of c-MYC role in DNA-PK-mediated activation of STING pathway in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - NRF2 activation promotes HER2-targeted tolerance and resistance in oesophageal adenocarcinoma through metabolic reprogramming to glutathione
Presenter: Wei Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - AURKB inhibition radiosensitises NSCLC by altering mitotic fate
Presenter: Kathryn Egerton
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Stratified control study on neuroendocrine differentiation and potential clinical markers in patients with limited-stage small-cell lung cancer
Presenter: Li Liu
Session: Cocktail & Poster Display session
Resources:
Abstract